Sorafenib-话题@MedSci - 梅斯（MedSci）

#Sorafenib#

8篇内容 | 1040人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1741297, encodeId=7b801e41297e2, content=<a href='/topic/show?id=f21916551da' target=_blank style='color:#2F92EE;'>#Sorafenib#</a>, objectTitle=沉默GRAMD1A能通过STAT5信号通路显著增强肝癌细胞Huh7对Sorafenib化疗及放疗敏感性, objectType=article, longId=221114, objectId=64d422111473, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64d422111473, replyNumber=0, likeNumber=61, createdTime=2022-07-30, rootId=0, userName=ms6127405442416114, userId=e32534916596, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64d422111473, moduleTitle=沉默GRAMD1A能通过STAT5信号通路显著增强肝癌细胞Huh7对Sorafenib化疗及放疗敏感性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=64d422111473)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1741295, encodeId=b44b1e4129515, content=<a href='/topic/show?id=f21916551da' target=_blank style='color:#2F92EE;'>#Sorafenib#</a>, objectTitle=J Clin Oncol：多纳非尼(Donafenib)与索拉非尼(Sorafenib)在不可切除或转移性肝癌一线治疗中的对比:一项随机、开放、平行对照的II-III期试验, objectType=article, longId=213616, objectId=dc3421361646, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc3421361646, replyNumber=0, likeNumber=139, createdTime=2022-04-17, rootId=0, userName=ms6127405442416114, userId=e32534916596, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc3421361646, moduleTitle=J Clin Oncol：多纳非尼(Donafenib)与索拉非尼(Sorafenib)在不可切除或转移性肝癌一线治疗中的对比:一项随机、开放、平行对照的II-III期试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=dc3421361646)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1741296, encodeId=384f1e41296d2, content=<a href='/topic/show?id=f21916551da' target=_blank style='color:#2F92EE;'>#Sorafenib#</a>, objectTitle=Front Oncol：仑伐替尼（lenvatinib）对比索拉非尼（Sorafenib）治疗晚期肝细胞癌的疗效：倾向评分匹配（PSM）分析, objectType=article, longId=219316, objectId=14432193166f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14432193166f, replyNumber=0, likeNumber=73, createdTime=2022-08-21, rootId=0, userName=ms6127405442416114, userId=e32534916596, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14432193166f, moduleTitle=Front Oncol：仑伐替尼（lenvatinib）对比索拉非尼（Sorafenib）治疗晚期肝细胞癌的疗效：倾向评分匹配（PSM）分析, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=14432193166f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1741298, encodeId=c8e01e41298e9, content=<a href='/topic/show?id=f21916551da' target=_blank style='color:#2F92EE;'>#Sorafenib#</a>, objectTitle=Oncologist: Sorafenib（索拉非尼）联合Capecitabine（卡培他滨）治疗既往治疗过的转移性结直肠癌患者的疗效和安全性, objectType=article, longId=221380, objectId=bb87221380d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb87221380d6, replyNumber=0, likeNumber=138, createdTime=2022-07-28, rootId=0, userName=ms6127405442416114, userId=e32534916596, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb87221380d6, moduleTitle=Oncologist: Sorafenib（索拉非尼）联合Capecitabine（卡培他滨）治疗既往治疗过的转移性结直肠癌患者的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bb87221380d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1741294, encodeId=be6b1e4129471, content=<a href='/topic/show?id=f21916551da' target=_blank style='color:#2F92EE;'>#Sorafenib#</a>, objectTitle=Br J Cancer：特泊替尼tepotinib与索拉非尼sorafenib对晚期肝细胞癌患者的治疗对比, objectType=article, longId=211713, objectId=6c95211e139d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c95211e139d, replyNumber=0, likeNumber=147, createdTime=2022-01-07, rootId=0, userName=ms6127405442416114, userId=e32534916596, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c95211e139d, moduleTitle=Br J Cancer：特泊替尼tepotinib与索拉非尼sorafenib对晚期肝细胞癌患者的治疗对比, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6c95211e139d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1741293, encodeId=d9831e41293d5, content=<a href='/topic/show?id=f21916551da' target=_blank style='color:#2F92EE;'>#Sorafenib#</a>, objectTitle=Lancet Oncol：晚期肾细胞癌中tivozanib和sorafenib治疗比较, objectType=article, longId=186219, objectId=9cd3186219f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9cd3186219f9, replyNumber=0, likeNumber=64, createdTime=2020-06-01, rootId=0, userName=ms6127405442416114, userId=e32534916596, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9cd3186219f9, moduleTitle=Lancet Oncol：晚期肾细胞癌中tivozanib和sorafenib治疗比较, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9cd3186219f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1741292, encodeId=44791e41292f9, content=<a href='/topic/show?id=f21916551da' target=_blank style='color:#2F92EE;'>#Sorafenib#</a>, objectTitle=CLIN CANCER RES：周细胞调节甲状腺癌Vemurafenib和Sorafenib治疗耐药, objectType=article, longId=156246, objectId=945a15624619, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=945a15624619, replyNumber=0, likeNumber=75, createdTime=2019-05-21, rootId=0, userName=ms6127405442416114, userId=e32534916596, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=945a15624619, moduleTitle=CLIN CANCER RES：周细胞调节甲状腺癌Vemurafenib和Sorafenib治疗耐药, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=945a15624619)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1741291, encodeId=b9ba1e41291cb, content=<a href='/topic/show?id=f21916551da' target=_blank style='color:#2F92EE;'>#Sorafenib#</a>, objectTitle=CLIN CANCER RES：Refametinib联合Sorafenib治疗RAS突变肝细胞癌, objectType=article, longId=151602, objectId=5b85151602b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b85151602b8, replyNumber=0, likeNumber=83, createdTime=2019-08-24, rootId=0, userName=ms6127405442416114, userId=e32534916596, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b85151602b8, moduleTitle=CLIN CANCER RES：Refametinib联合Sorafenib治疗RAS突变肝细胞癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5b85151602b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Sorafenib

2020-05-29

ms6127405442416114 (审核中...)

前往app查看评论内容

#Sorafenib#

沉默GRAMD1A能通过STAT5信号通路显著增强肝癌细胞Huh7对Sorafenib化疗及放疗敏感性

2022-07-30

ms6127405442416114 (审核中...)

前往app查看评论内容

#Sorafenib#

J Clin Oncol：多纳非尼(Donafenib)与索拉非尼(Sorafenib)在不可切除或转移性肝癌一线治疗中的对比:一项随机、开放、平行对照的II-III期试验

2022-04-17

ms6127405442416114 (审核中...)

前往app查看评论内容

#Sorafenib#

Front Oncol：仑伐替尼（lenvatinib）对比索拉非尼（Sorafenib）治疗晚期肝细胞癌的疗效：倾向评分匹配（PSM）分析

2022-08-21

ms6127405442416114 (审核中...)

前往app查看评论内容

#Sorafenib#

Oncologist: Sorafenib（索拉非尼）联合Capecitabine（卡培他滨）治疗既往治疗过的转移性结直肠癌患者的疗效和安全性

2022-07-28

ms6127405442416114 (审核中...)

前往app查看评论内容

#Sorafenib#

Br J Cancer：特泊替尼tepotinib与索拉非尼sorafenib对晚期肝细胞癌患者的治疗对比

2022-01-07

ms6127405442416114 (审核中...)

前往app查看评论内容

#Sorafenib#

Lancet Oncol：晚期肾细胞癌中tivozanib和sorafenib治疗比较

2020-06-01

ms6127405442416114 (审核中...)

前往app查看评论内容

#Sorafenib#

CLIN CANCER RES：周细胞调节甲状腺癌Vemurafenib和Sorafenib治疗耐药

2019-05-21

ms6127405442416114 (审核中...)

前往app查看评论内容

#Sorafenib#

CLIN CANCER RES：Refametinib联合Sorafenib治疗RAS突变肝细胞癌

2019-08-24

科室
- - 订阅+
  - 更多科室
工具
服务